What is the role of rituximab in the treatment of Takayasu arteritis?

Updated: Nov 14, 2018
  • Author: Jefferson R Roberts, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Rituximab, a chimeric IgG1 antibody that binds to CD20 expressed on the surface of B cells, has been shown to improve clinical signs and symptoms of Takayasu arteritis. [45] Although the pathogenesis of Takayasu arteritis is not believed to be mediated by the humoral immune system, B cells are believed to have an antibody-independent effect, which may modulate regulatory T-cell immune reactions against foreign and self-antigens. No large trial has proved this finding.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!